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Background: There is no published algorithm predicting asthma crisis events 
(Accident and Emergency (A&E) attendance, hospitalisation or death) using routinely 
available electronic health record (EHR) data.  
Aim:  To develop an algorithm to identify individuals at high risk of an asthma crisis 
event. 
Design and Setting: Database analysis from primary care EHRs. 
Method: Multivariable logistic regression was applied to a dataset of 61,861 people 
with asthma from England and Scotland using the Clinical Practice Research 
Datalink. External validation was performed using the Secure Anonymised 
Information Linkage databank of 174,240 patients from Wales. Outcomes were one 
or more hospitalisation (development dataset) and asthma-related hospitalisation, 
A&E attendance or death (validation dataset) within a 12-month period. 
Results: Risk factors for asthma-related crisis events included previous 
hospitalisation, older age, underweight, smoking and blood eosinophilia. The 
prediction algorithm had acceptable predictive ability with a Receiver Operating 
Characteristic (ROC) of 0.71 (0.70, 0.72) in the validation dataset. Using a cut-point 
based on the 7% of the population at greatest risk results in a positive predictive 
value of 5.7% (95% CI 5.3 – 6.1) and a negative predictive value of 98.9% (98.9 – 
99.0), with sensitivity of 28.5% (26.7 – 30.3) and specificity of 93.3% (93.2 – 93.4); 
they had an event risk of 6.0% compared 1.1% for the remaining population. 
Eighteen people would be “needed to follow” to identify one admission. 
Conclusions: This externally validated algorithm has acceptable predictive ability for 
identifying patients at high risk of asthma-related crisis events and excluding 







Asthma, asthma attack, risk, prediction, algorithm. 
 
How this fits in 
Risk stratification is commonly undertaken in primary care but there are no validated 
prediction algorithms for people with asthma using routine data. An algorithm was 
developed using a primary care dataset and externally validated showing acceptable 
predictive ability with a Receiver Operating Characteristic (ROC) of 0.71 (95% CI 
0.70 – 0.72). The 7% of the population most at risk had an event rate of 6.0% 
compared 1.1% for the remaining population. This algorithm can be used to identify 
individuals at high risk of an asthma-related crisis event from primary care electronic 






The challenge of reducing unplanned hospital admissions and avoidable deaths in 
common chronic conditions, such as asthma, remains unresolved. Despite effective 
treatments, evidence-based guidelines(1) and financially incentivised community-
based chronic disease management (via the Quality and Outcomes Framework(2)), 
each year in the UK an average of 1500 people die(3) and 93,000 are hospitalised 
due to asthma(4). Identification of those at increased risk of these events is 
beneficial both at an individual level to tailor disease management, and at a 
population level to inform and modify processes of care. 
 
Many risk factors for poor asthma outcomes have been identified,(5-8) some of 
which have been combined into risk algorithms including the Asthma UK “Asthma 
attack risk checker”(9), Asthma Disease Activity Score(10) and Wheeze frequency, 
Admissions, Reliever use and Step on BTS medication guidelines (WARS) 
score(11).  Recently an algorithm has been developed to identify children at risk of 
life-threatening asthma(12). These have been derived from small datasets including 
those from clinical trials or the variables used in the prediction tools have required 
up-to-date personal characteristics including psychosocial characteristics or 
adherence to medication for which comprehensive data are difficult to obtain in large 
populations(13). An algorithm to identify patients at greatest risk of poor outcomes 
using electronic healthcare data would overcome this problem and enable a register 
of high-risk patients to be generated efficiently.  
 
Most prediction algorithms have defined a severe asthma attack as one that requires 
oral corticosteroid therapy or hospital attendance/admission(14). However, this 
 
 
composite scoring includes variables which are not necessarily co-linear.  Early 
treatment with prednisolone may stop the deterioration and prevent an Accident and 
Emergency (A&E) attendance and as such this composite definition may mask the 
benefits of prompt management of an attack, with increased prednisolone treatment 
and reduced hospitalisations(13). Therefore, it is important to develop algorithms that 
identify these two risks separately. 
 
We aimed to develop and validate a prediction tool to identify individuals at high risk 
of an asthma related crisis event (A&E attendance, hospital admission or death due 
to asthma) during the following 12 months, calculated from routinely captured 




(i) Derivation dataset 
An analytical dataset was used from a published cohort study(15) which used a 
database of people with physician diagnosed and recorded asthma (with no 
subsequent code for asthma resolved) aged between 12 and 80 years and 
measurement of full blood count (FBC) at any time in the past, with two years of 
continuous data, registered at 650 primary care practices in the United Kingdom. 
The dataset comprised data from the Clinical Practice Research Datalink (CPRD, 
www.cprd.com) (16) between 2001 and 2012. Although the CPRD database 
contains record-linked primary and secondary care data, including reason for 
admission to hospital, only data from primary care were used to derive the algorithm 
because EHRs in UK primary care do not consistently code secondary care events. 
 
 
However, both primary and secondary care data were used when assessing the 
outcome.  
 
(ii) Validation dataset. 
A separate dataset of patients from the Secure Anonymised Information linkage 
(SAIL) databank (17, 18) who were registered at 340 general practices in Wales was 
used to validate the algorithm. Record-linked data from primary and secondary care 
were available for individual patients and included reason for admission to hospital. 
Data on asthma outcomes, healthcare interactions (including GP consultations) and 
prescribed medications were obtained from the SAIL Databank. 
 
Eligibility.  
Patients included in the existing analytical dataset for the derivation of the at-risk 
algorithm comprised those with ‘active asthma’ (i.e. with a coded diagnosis of 
asthma and a prescription for asthma treatment in the previous 12 months(19)), no 
diagnosis of any other chronic respiratory disease, a valid blood eosinophil count (≤ 
5,000 blood eosinophils/microlitre (µL)) and complete data for the baseline and 
outcome years (the year prior to and the year following the last eosinophil count). 
 
Patients included in the SAIL validation dataset comprised those with at least one 
“asthma diagnosis” code before 31/12/2011, no “asthma resolved” codes between 
1/1/2010 and 31/12/2011, and at least one asthma prescription (bronchodilator, 
corticosteroid or leukotriene receptor antagonist) code between 1/1/2010 and 
31/12/2010. Patients were continuously registered at one general practice between 
 
 
1/1/2010 and 31/12/2010 (baseline data collection year) and continually registered 
(or died) between 1/1/2011 and 31/12/2011 (outcome year).  
 
Predictors. 
Details of all variables considered as potential predictors for the at-risk algorithm are 
shown in Supplementary Table S1. These included age, sex, smoking history, 
comorbidities, respiratory related medication, healthcare contacts and blood 
eosinophil count. For diagnostic variables (e.g. ischaemic heart disease, diabetes), 
Read Codes (coded clinical terms) were queried anytime up to the end of the 
baseline year (i.e. from 'ever' to '31/12/2010') from the validation and derivation 
databases. Similarly, for eosinophil count, body mass index (BMI), and smoking 
status, the most recent codes any time before 31/12/2010 were used. For the rest of 
the variables (prescriptions for asthma, allergic rhinitis, diabetes, anxiety and 
depression, as well as paracetamol use (which is positively associated with 
asthma(20)), lower respiratory tract infection (LRTI) consultations, allergic rhinitis 
diagnosis), the codes were queried between 01/01/2010 and 31/12/2010.   
 
Outcome. 
The outcome was defined as one or more hospitalisations within 12 months for the 
development of the algorithm. For the validation of the algorithm we defined the 
outcome as a crisis event which comprised an asthma-related hospitalisation, A&E 







Univariate logistic regression models were used to identify baseline measures of 
disease severity, patient demographics and comorbidities predictive of one or more 
future events. Variables showing an association (p<0.05) with an asthma 
exacerbation resulting in hospital admission in univariable analyses were entered 
into a multivariable model, which was reduced using backward elimination to 
produce a final list of predictors of hospital admission. No model updating was 
undertaken. 
 
The final model was used to create ‘at-risk’ scores indicating the risk of an asthma-
related crisis event for each patient in the dataset. To do this, coefficients for those 
factors present in each patient were summed, along with the intercept, to obtain the 
risk score (x) which is the logit of the probability of asthma-related attendance at 
A&E or hospital admission; the probability is given by ex/(1+ex). We did not 
investigate internal validation, as we used a separate dataset to perform external 
validation. The calibration slope coefficient was estimated by splitting the predicted 
risk into 10 groups, based on quintiles, and calculating the percentage of people with 
the outcome in these estimating a linear regression model with the predicted risk 
group against the actual risk. 
 
We assessed discrimination (the ability to distinguish between those who do and do 
not experience the outcome) by calculating the Receiver Operating Characteristic 
(ROC) for the risk scores. In addition, we calculated the specificity, sensitivity, 
positive predictive values (PPV) and negative predictive values (NPV) for five 
different ’at-risk’ cut-offs (top 1%, 2%, 5%, 7% and 10%) for the risk scores for both 
 
 
the derivation and the validation datasets.  The overall goodness of fit of the score 
was assessed by estimating the pseudo R2 from the logistic regression model. 
Assuming an asthma prevalence of 6-7%, a 7% cut-off would, on average, identify 
the most at risk 42-49 individuals from a practice of 10,000 patients. A sensitivity 







The derivation and validations data sets comprised 58,619 and174,240 people 
respectively (Figure 1) The average age of participants in the derivation dataset was 
50 years and 44 years in the validation dataset, with more females in both datasets 
(Table 1). There were proportionally more people receiving Global Initiative for 
Asthma (GINA) treatment step 4 or 5 (medium or high dose inhaled corticosteroid 
and long acting beta agonist/muscarinic antagonist +/- add on therapies) and more 
with a diagnosis of or treatment for rhinitis in the derivation database. There were 
differences in the dataset in terms of smoking status, BMI, anxiety and depression 
and paracetamol usage. The outcome was present in 1.65% of individuals in the 
derivation and 1.40% in the validation dataset.  
 
The results of the logistic regression are presented in Table 2, which gives the 
estimated weight of each variable and describes the algorithm used to predict 
asthma crisis events. The overall ability of the algorithm to discriminate between 
patients who subsequently had an asthma-related crisis event and those who did not 
was acceptable (Table 3) and similar in the derivation data (ROC = 0.72 (95% CI: 
0.71, 0.74) to the validation data (ROC = 0.71 (95% CI: 0.70, 0.72).  Using a cut-
point based on the 7% of the population at greatest risk results in a positive 
predictive value of 5.7% (95% CI 5.3 – 6.1) and a negative predictive value of 98.9% 
(98.9 – 99.0), with 28.5% (26.7 – 30.3) sensitivity of 28.5% (26.7 – 30.3) and 
specificity of 93.3% (93.2 – 93.4) (Table 3). The discriminative ability of the algorithm 
was similar in the validation cohort when the outcome was confined to hospitalisation 
only (Table S2). These individuals had a risk of event of 5.68% (Table 4) and 3.31% 
 
 
when considering hospitalisation only (Table S3). The at-risk algorithm showed 
acceptable prognostic performance in the validation data with a 5.4 -fold higher 
asthma-related crisis event rate in the high risk-group (6.0%) versus the rest of the 
population (1.1%) at the 7% cut-off (Table 5) or an absolute difference of 4.9%.  
 
The calibration slopes showed acceptable agreement between deciles of mean risk 
score and proportions of people experiencing asthma-related crisis events within 
each decile group, with data points close to the line of equality. The slope coefficient 
for the development dataset was 0.99 (95%CI 0.92 to 1.05), while that for the validation 





We have derived and externally validated an algorithm, containing hospitalisation, 
older age, underweight, smoking and blood eosinophilia, to identify individuals at 
increased risk of experiencing an asthma-related crisis event using data that are 
routinely available in UK primary care EHRs. This had acceptable overall 
characteristics with ROC of 0.72 in the derivation and 0.71 in the validation cohorts 
respectively. Using the top 7% of the score as a cut-off, our algorithm correctly 
identified 28.5% of the asthma population most at risk and 93.3% of those not at risk. 
A practice can expect a crisis event to occur in 6.0% of the ‘high risk’ group 
compared to 1.1% of the rest of the asthma population. Eighteen people would be 
“needed to follow” to identify one admission. The algorithm can identify people who 
are at a 5-fold increased risk (absolute difference of 5%) of an asthma-related crisis 
event compared to those not at-risk. 
 
Strengths and Limitations 
The main strength of this study is that we used two separate large databases 
capturing people from different geographical areas with record linkage between 
primary and secondary care data. The generalisability of the algorithm is illustrated 
by its similar behaviour in two different datasets. We deliberately ignored the data on 
cause (asthma related or not) for hospital admission when deriving the algorithm as 
this information, although predictive of future events, is not routinely available in 
primary care datasets. However, by linking primary care with secondary care data for 
the purposes of assessing the outcome, we were able to confirm that our algorithm 




The limitations were that patients in the derivation, but not validation, cohort needed 
to have had a valid FBC to be entered into the database (although specific values 
such as eosinophil counts were not required). This is likely to have resulted in 
differences in some of the characteristics for example age, gender, asthma severity, 
number of comorbidities. We do not believe that there is any difference in the 
diagnosis or management of people with asthma between Wales and England as 
both countries follow National Guidelines(1). The databases contained data which 
are now a decade old (validation 2001-2012, validation 2011-2012) and asthma 
guidelines have been update in this time(1). These modifications have included the 
use of high dose inhaled corticosteroids to abort an asthma attack(21), vitamin D 
monitoring and therapy(22) as well as the use of monoclonal antibody therapies(23).  
However, there have been no significant changes to the understanding of the 
aetiology of asthma crises or deaths since the data were collected and the software 
systems and determinants of coding decisions in day to day practice remain 
comparable. We did not have access to information on medication adherence or 
social circumstances. Socioeconomic status has been shown to be a risk factor for 
hospitalisation(24) and also independent predictor for life threatening asthma in 
children(12). Unfortunately, routine data do not contain this information although 
algorithms have been developed for assessing prescription uptake(25) and 
socioeconomic status is available from postcode data(26) both of which may be 
applied to future algorithms. We did not have death or A&E data in the derivation 
cohort, but we did in the validation cohort. However, we have shown that the 
performance of the prediction algorithm is similar when considering hospitalisation or 
hospitalisation, A&E attendance or death. Whilst the number of short-acting beta-
 
 
agonist scripts were included in our list of potential variables, long-acting beta-
agonist as monotherapy, which has been described as a risk factor in asthma 
deaths(27), was not as this regime is rarely prescribed(28). This algorithm does not 
predict community-based asthma attacks requiring oral prednisolone. 
 
Comparison with existing literature 
The WARS score had a ROC of 0.83 for prednisolone use (11) but the performance 
of the score in terms of crisis events is unknown. Likewise, the performance 
measurements of the Risk Score developed by Bateman et al(10) for asthma attacks 
are not published. However the Respiratory Effectiveness Group Initiative published 
an algorithm to predict risk of two or more attacks in the subsequent two years with 
an ROC of 0.79 (95% CI 0.78-0.79)(29).  Recent evidence (27), suggests that 
disease severity is an unreliable measure of risk and, indeed, our results confirmed 
that GINA treatment step ‘no therapy’ was as significant a risk factor as step 4-5.  
 
In terms of non-respiratory hospitalisation prediction algorithms, the QRISK2 score 
which is widely used within the NHS to predict cardiovascular events has a R2 of 
43.5 and 38.4, and ROC statistic of 0.82 and 0.79 in females and males, 
respectively(30). A systematic review of risk prediction models to predict emergency 
admission in community dwelling adults(31) identified 27 different risk prediction 
models and showed that models using clinical data (as in our algorithm) out-
performed those using self-reported data with C-statistics ranging from 0.63 to 0.83. 
Our algorithm, which utilised clinical data, had a comparable level of calibration (C-




We collected our outcome data as events over a 12-month period in order to avoid 
seasonal variations. Our algorithm therefore predicts hospitalisation within the 
following year. However, an individual’s risk status can change if, for example, they 
had a hospitalisation just within or out with a 365-day period. Different algorithms can 
show substantial variation in risk at the individual level (32) and should complement 
physician assessment based on knowledge about individuals. Nevertheless, the 
growing workloads on primary care clinicians and the ongoing challenge of rising 
unplanned admissions and avoidable deaths makes accurate identification and 
targeting of the highest risk individuals an essential part of primary care strategy.  
 
Implications for research and/or practice 
Primary care software systems routinely use prompts to alert clinicians to overdue 
asthma reviews and the over-ordering, and by implication over-use, of short acting 
beta agonists (SABA). Both are helpful markers of risk which are not always 
recognised as such(13, 33, 34), but they do not reflect the range and complexity of 
factors found in patients most at risk of adverse outcomes(27, 35). Guidelines(1) 
recommend that patients are assessed for risk of future attacks. The indicators 
recommended include a history of previous attacks, SABA use and other markers of 
disease control, atopy and environmental tobacco exposure in children, and in 
adults, smoking, obesity and depression. In April 2020, Quality and Outcome 
Framework (QOF) indicators for disease control were changed from the Three Royal 
Colleges of Physicians Questions to the Asthma Control Test Score plus the number 
of exacerbations in the previous twelve months. Achieving these new indicators 
requires more clinician time and greater participation from patients. Failure to attend 




Our algorithm simplifies the collection and weights the significance of multiple risk 
factors. It has the potential to save clinicians’ time and provide accurate real-time 
assessments of patients’ risk. It does not require patients to attend and therefore 
also by-passes the dangers of inverse care associated with poor attendance at 
appointments. It also concurs with, and provides a mechanism to identify, important 
markers highlighted in the National Review of Asthma Deaths (NRAD) report such as 
patients on no treatment for their asthma at all (27). It can be used to generate alerts 
or prompts to identify patients, at high risk of asthma crisis events (A&E attendance, 
hospitalisation or death), when their EHRs are accessed so that care can be 
targeted appropriately.  
 
The algorithm is currently being used in a study to validate the role of at-risk asthma 
registers in primary care(36). Further work is also needed to explore some of the 
unexpected findings such as low BMI, and to find a way to incorporate important 
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